Subcutaneous · GLP-1 agonist
Efsubaglutide Alfa
14 trials in this molecule. Source: ClinicalTrials.gov, as of November 5, 2026.
Trials
14
Ongoing
6
Recruiting
3
Completed
7
Sites
129
Countries
3
Endpoints
204
Composite endpoints
3
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Where the program stands
Trials by phase
Phase 1
4
Phase 2
4
Phase 2/3
3
Phase 3
1
Phase 4
1
Not applicable
1
Trials by status
Not yet recruiting
2
Recruiting
3
Active, not recruiting
1
Completed
7
Unknown
1
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Glycemic / diabetes
52
Safety / tolerability / PK
50
Weight & body composition
44
Other (unclassified)
29
Cardiometabolic biomarkers
21
MASH / liver
3
Renal / kidney
2
Other clinical outcomes
2
Patient-reported / QoL
1
Top 20 metrics across this asset's endpoints
AUC₀-∞Safety/PK
5
CmaxSafety/PK
2
Fasting glucose, changeGlycemic
2
TmaxSafety/PK
1
Half-lifeSafety/PK
1
Treatment-emergent AEs (any)Safety/PK
1
Body weight, absolute change (kg)Weight
1
Immunogenicity (ADA)Safety/PK
1
Body weight, % changeWeight
1
Total fat massWeight
1
HbA1c, changeGlycemic
1
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
⌘K
14 of 14
Showing 1-14 of 14 trials